Severity of HIV disease and risk of disease progression as determined by presence or history of HIV-related serious or AIDS-defining illnesses, and the child’s CD4+ cell count and plasma HIV RNA level;
Availability of appropriate (and palatable) drug formulations for the child and pharmacokinetic information on appropriate dosing in the child’s age group.